Profile data is unavailable for this security.
About the company
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
- Revenue in USD (TTM)8.19m
- Net income in USD-45.87m
- Incorporated2006
- Employees65.00
- LocationOcugen Inc11 GREAT VALLEY PARKWAYMALVERN 19355United StatesUSA
- Phone+1 (484) 328-4701
- Fax+1 (302) 655-5049
- Websitehttps://ocugen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nkarta Inc | 0.00 | -107.91m | 276.59m | 150.00 | -- | 0.6103 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Editas Medicine Inc | 67.03m | -193.45m | 278.77m | 265.00 | -- | 1.20 | -- | 4.16 | -2.36 | -2.36 | 0.8183 | 2.81 | 0.1447 | -- | 52.99 | 252,954.70 | -41.75 | -29.85 | -48.49 | -33.19 | -- | -- | -288.59 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Zura Bio Ltd | 0.00 | -27.94m | 279.33m | 14.00 | -- | 1.78 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Akebia Therapeutics Inc | 174.50m | -40.44m | 279.68m | 167.00 | -- | -- | -- | 1.60 | -0.2024 | -0.2024 | 0.8803 | -0.1608 | 0.7364 | 1.36 | 7.07 | 1,044,892.00 | -17.07 | -37.42 | -29.47 | -56.00 | 82.59 | 69.13 | -23.18 | -82.25 | 0.8222 | -4.41 | 8.89 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Abeona Therapeutics Inc | 0.00 | -52.60m | 279.81m | 84.00 | -- | 3.67 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
AVITA Medical Inc | 54.14m | -49.83m | 281.21m | 207.00 | -- | 11.74 | -- | 5.19 | -1.95 | -1.95 | 2.12 | 0.9216 | 0.6217 | 1.46 | 7.23 | 261,541.10 | -57.22 | -- | -68.00 | -- | 86.80 | -- | -92.04 | -- | 4.81 | -13.95 | 0.6315 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Alto Neuroscience Inc | -100.00bn | -100.00bn | 281.72m | 78.00 | -- | 1.57 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -50.53m | 283.10m | 57.00 | -- | 1.08 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Lexeo Therapeutics Inc | 0.00 | -77.22m | 286.31m | 58.00 | -- | 1.74 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Ocugen Inc | 8.19m | -45.87m | 290.74m | 65.00 | -- | 15.36 | -- | 35.49 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Tscan Therapeutics Inc | 12.20m | -104.41m | 291.89m | 175.00 | -- | 1.14 | -- | 23.93 | -1.05 | -1.05 | 0.1225 | 4.82 | 0.0353 | -- | -- | 79,220.78 | -30.19 | -- | -33.78 | -- | -- | -- | -855.84 | -- | -- | -- | 0.1066 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Atea Pharmaceuticals Inc | 0.00 | -176.00m | 292.10m | 75.00 | -- | 0.613 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -123.44m | 293.15m | 33.00 | -- | 1.27 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Personalis Inc | 80.03m | -81.45m | 294.26m | 223.00 | -- | 2.45 | -- | 3.68 | -1.63 | -1.63 | 1.59 | 2.12 | 0.3683 | 6.68 | 6.94 | 358,865.50 | -37.49 | -28.84 | -43.81 | -34.72 | 27.76 | 28.65 | -101.78 | -96.01 | 3.05 | -- | 0.0199 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
Sutro Biopharma Inc | 169.36m | -124.45m | 295.89m | 304.00 | -- | 1.94 | -- | 1.75 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
PepGen Inc | 0.00 | -89.14m | 303.08m | 64.00 | -- | 1.94 | -- | -- | -3.30 | -3.30 | 0.00 | 4.78 | 0.00 | -- | -- | 0.00 | -47.47 | -- | -52.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 11.91m | 4.63% |
Geode Capital Management LLCas of 30 Jun 2024 | 5.90m | 2.30% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.70m | 1.44% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 2.61m | 1.01% |
Millennium Management LLCas of 31 Mar 2024 | 1.93m | 0.75% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 1.20m | 0.47% |
Two Sigma Investments LPas of 31 Mar 2024 | 1.03m | 0.40% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 956.73k | 0.37% |
HRT Financial LLCas of 31 Mar 2024 | 806.50k | 0.31% |
Group One Trading LPas of 31 Mar 2024 | 624.80k | 0.24% |